Renalytix's KidneyIntelX included in draft KDIGO 2023 chronic kidney disease guidelines

Renalytix plc

Public comment period on draft KDIGO 2023 guidelines closed; final version expected Q4 2023.
KDIGO is a global nonprofit; guidelines are followed by clinicians worldwide.
Inclusion, if finalized, could drive broader adoption and reimbursement for KidneyIntelX in US and abroad.
Renalytix notes inclusion in draft does not guarantee inclusion in final guidelines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.